SCHEMBL240117

SCHEMBL240117

CCCC(C)C(=O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.46
AKR1A1 P14550 1/20 0.46
CHRM3 P20309 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
ADRA1A P35348 1/20 0.46
HRH1 P35367 1/20 0.46
DRD3 P35462 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ACE2 Q9BYF1 1/20 0.39
TSHR P16473 3/20 0.39
CYP3A4 P08684 2/20 0.39
NFKB1 P19838 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
FDPS P14324 1/20 0.39
CA1 P00915 2/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003475 0.85 CA1 (0.50) ACE2FDPSCA1SLC1A3SLC1A2
SCHEMBL6681186 0.85 CA1 (0.50) ACE2FDPSCA1SLC1A3SLC1A2
SCHEMBL6674983 0.85 CA1 (0.50) ACE2FDPSCA1SLC1A3SLC1A2
SCHEMBL10352730 0.83 CA1 (0.59) ACE2FDPSCA1
SCHEMBL18759148 0.81 CA1 (0.57) ACE2FDPSCA1
SCHEMBL8249566 0.79 CHRM1 (0.40) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL8105244 0.79 GABRP (0.37) ACE2GABRR1CYP1A2
SCHEMBL17449760 0.78
SCHEMBL148477 0.78
SCHEMBL3860250 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125513-A1 CURABLE RESIN COMPOSITIONS ILLUMINA INC (US) 2026-05-07 US claimed
EP-4405750-B1 CURABLE RESIN COMPOSITIONS ILLUMINA INC (US) 2026-04-22 EP claimed
US-12559627-B2 Curable resin compositions ILLUMINA, INC. (US) 2026-02-24 US claimed
EP-4405749-A2 CURABLE RESIN COMPOSITIONS Illumina, Inc. (US) 2024-07-31 EP claimed
EP-4405750-A1 CURABLE RESIN COMPOSITIONS Illumina, Inc. (US) 2024-07-31 EP claimed
WO-2023046813-A2 CURABLE RESIN COMPOSITIONS ILLUMINA CAMBRIDGE LIMITED (GB) 2023-03-30 WO claimed
WO-2023046814-A1 CURABLE RESIN COMPOSITIONS ILLUMINA CAMBRIDGE LIMITED (GB) 2023-03-30 WO claimed
US-20230100285-A1 CURABLE RESIN COMPOSITIONS ILLUMINA, INC. 2023-03-30 US claimed
JP-2002542797-A 2002-12-17 JP claimed
US-6403144-B1 LECITHIN ANTISTICK AGENT, NUCLEOTIDE FLAVOR ENHANCER, POLYDIMETHYLSILOXANE ANTIFOAM AGENT, RELATIVELY LOW AMOUNTS YET PROVIDE IMPROVED FLAVOR, TEXTURE AND AROMA OF COOKING OIL, COOKING SPRAY, AND SHORTENING THE PROCTER & GAMBLE CO. 2002-06-11 US claimed
US-20020045001-A1 Food preparation compositions THE J.M. SMUCKER COMPANY 2002-04-18 US claimed
EP-1176879-A1 FOOD PREPARATION COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2002-02-06 EP claimed
WO-2000065933-A1 FOOD PREPARATION COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2000-11-09 WO claimed
US-20260125513-A1 CURABLE RESIN COMPOSITIONS ILLUMINA INC (US) 2026-05-07 US disclosed
EP-4405750-B1 CURABLE RESIN COMPOSITIONS ILLUMINA INC (US) 2026-04-22 EP disclosed
US-12559595-B2 Curable resin compositions ILLUMINA, INC. (US) 2026-02-24 US disclosed
WO-1999027120-A1 METHODS AND MEANS FOR MODIFICATION OF GLUCOSINOLATES IN PLANTS PLANT BIOSCIENCE LIMITED (GB) 1999-06-03 WO disclosed
EP-0408674-A1 ALTERNATIVE ENERGY SUBSTRATE Kabi Pharmacia AB (SE) 1991-01-23 EP disclosed
EP-0366632-A1 Alternative energy substrates KABIVITRUM AB (SE) 1990-05-02 EP disclosed
WO-1990002726-A1 ALTERNATIVE ENERGY SUBSTRATE KABIVITRUM AB (SE) 1990-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559627-B2 Curable resin compositions PSMB2, ECPAS, RPS26 CHRM1 2711/4885AKR1A1 4400/4885CHRM3 3783/4885
US-12559595-B2 Curable resin compositions ACR, RARA, RAD51 CHRM1 2248/4885AKR1A1 1615/4885CHRM3 2413/4885
US-20260125513-A1 CURABLE RESIN COMPOSITIONS RAD51, ACR, ACMSD CHRM1 3309/4885AKR1A1 2354/4885CHRM3 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.